Dr. Moraes is a central nervous system and brain metastasis clinical fellow, and Dr. Shultz is clinician investigator and assistant professor, Department of Radiation Oncology, University of Toronto, ON, Canada, and Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. Dr. Khuntia is senior vice president and chief medical officer, Varian Medical Systems, Palo Alto, CA, and radiation oncologist at Precision Cancer Specialists, Los Gatos, CA. Dr. Murphy is assistant professor, Dr. Chao is associate professor, and Dr. Suh is professor and chairman, Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH.
Conflicts of interest: Dr. Suh: consultant and research support from Varian Medical Systems, Palo Alto, CA; honorarium from Philips Medical Systems, Amsterdam, The Netherlands. Dr. Chao: honorarium from Varian Medical Systems; Zeiss, Oberkochen, Germany; and AbbVie, North Chicago, IL. Dr. Khuntia: employee of Varian Medical Systems.
Dr. Ampil is a professor and Gamma Knife radiosurgery radiation oncologist; Dr. Vora is a fellow in the Department of Pathology; Dr. Hardjasudarma, is a professor in the Department of Radiology; Dr. Nanda, is a professor and chair of the Department of Neurosurgery, Louisiana State University Health Sciences Center, Shreveport, LA.
Dr. Chino is chief resident at Duke University Radiation Oncology, Durham, NC.
Dr. Grass is an assistant member and Dr. Mills is a radiation oncology resident, Department of Radiation Oncology, Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Dr. Scott is an assistant professor, Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH. Dr. Eschrich is a senior member, Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute. Dr. Torres-Roca is a senior member, Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute. Disclosure: Drs. Scott, Torres-Roca and Eschrich report intellectual property (IP); Drs. Scott and Torres-Roca report IP regarding genomically adjusted radiation dose (GARD), and Drs. Eschrich and Torres-Roca report stock in Cvergenx. None of the authors received outside funding for the production of this original manuscript and no part of this article has been previously published elsewhere.
Drs. Neyman, Ouzidane, Godley, Djemil, and Chao are in the Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH.